Circulating Tumor Cells Market Size, Share & Trends Analysis Report By Application (Clinical/Liquid Biopsy, Research), By Specimen (Bone Marrow, Blood), By Product, By Technology, By End-use, By Region, And Segment Forecasts, 2024 - 2030
Circulating Tumor Cells Market Growth & Trends
The global circulating tumor cells market size is anticipated to reach USD 27.55 billion by 2030, expanding at a CAGR of 13.62% from 2024 to 2030, according to a new report by Grand View Research, Inc. This is attributed to rising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.
In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management—early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used to diagnose or monitor cancer, is expected to boost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.
The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the near future.
However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up the CTC market’s growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.
Circulating Tumor Cells Market Report Highlights
- Based on technology, CTC detection & enrichment methods dominated the market in 2023 with a revenue share of 66.2% owing to the increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
- The CTC analysis segment is expected to grow at the fastest CAGR from 2024 to 2030 due to the growing application potential of CTC analysis for investigational research, drug development, and biomarker studies
- Based on application, the research segment dominated the market in 2023 and it is expected to witness the fastest CAGR from 2024 to 2030
- Kits & reagent dominated the product segment in 2023, and it is expected to witness the fastest growth in forecast period of 2024-2030
- Based on specimen, the blood segment dominated the market in 2023. The other body fluids segment is expected to witness the fastest CAGR from 2024 to 2030
- Based on end-use, the research & academic institutes segment dominated the market in 2023 due to increasing focus on research and development activities for cancer diagnosis and treatment
- North America dominated the CTC market in 2023, owing to factors such as the presence of key market players Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., and LungLife AI, Inc. and the growth in pharmaceutical & biotechnology research sectors in this region
- Asia Pacific is expected to register the fastest CAGR over the forecast period due to several companies expanding their presence in countries like Japan
- Chapter 1. Circulating Tumor Cells Market: Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Application
- 1.2.3. Product
- 1.2.4. Specimen
- 1.2.5. End-use
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Circulating Tumor Cells Market: Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights
- Chapter 3. Circulating Tumor Cells Market: Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Advancements in chip technology
- 3.2.1.2. Expanding applications of CTCs
- 3.2.1.3. Growing demand for early and rapid cancer diagnosis
- 3.2.1.4. Growing incidence of cancer
- 3.2.2. Market restraint analysis
- 3.2.2.1. Consistency-related challenges in CTC detection and enrichment
- 3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
- 3.2.2.3. Lower applicability of CTCs in rare cancers
- 3.3. Circulating Tumor Cells Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
- Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis
- 4.1. Technology Market Share, 2023 & 2030
- 4.2. Global Circulating Tumor Cells Market by Technology Outlook
- 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.3.1. CTC Detection & Enrichment Methods
- 4.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.1.2. Immunocapture (Label-based)
- 4.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.1.2.2. Positive Selection
- 4.3.1.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.1.2.3. Negative Selection
- 4.3.1.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.1.3. Size-based Separation (Label-free)
- 4.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.1.3.2. Membrane-based
- 4.3.1.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.1.3.3. Microfluidic-based
- 4.3.1.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.1.4. Density-based Separation (Label-free)
- 4.3.1.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.1.5. Combined Methods
- 4.3.1.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2. CTC Direct Detection Methods
- 4.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.2. SERS
- 4.3.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.3. Microscopy
- 4.3.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.2.4. Others
- 4.3.2.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 4.3.3. CTC Analysis
- 4.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2023 & 2030
- 5.2. Global Circulating Tumor Cells Market by Application Outlook
- 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.3.1. Clinical/ Liquid Biopsy
- 5.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.3.1.2. Risk Assessment
- 5.3.1.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.3.1.3. Screening and Monitoring
- 5.3.1.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.3.2. Research
- 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.3.2.2. Cancer Stem Cell & Tumorogenesis Research
- 5.3.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 5.3.2.3. Drug/Therapy Development
- 5.3.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis
- 6.1. Product Market Share, 2023 & 2030
- 6.2. Global Circulating Tumor Cells Market by Product Outlook
- 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.3.1. Kits & reagents
- 6.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.3.2. Blood collection tubes
- 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Devices or systems
- 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis
- 7.1. Specimen Market Share, 2023 & 2030
- 7.2. Global Circulating Tumor Cells Market by Specimen Outlook
- 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.3.1. Blood
- 7.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.2. Bone marrow
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Other body fluids
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- Chapter 8. Circulating Tumor Cells Market: End-use Estimates & Trend Analysis
- 8.1. End-use Market Share, 2023 & 2030
- 8.2. Global Circulating Tumor Cells Market by End-use Outlook
- 8.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 8.3.1. Research and academic institutes
- 8.3.1.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.3.2. Hospital and clinics
- 8.3.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- 8.3.3. Diagnostic centers
- 8.3.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
- Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Share Analysis, 2023 & 2030
- 9.2. North America
- 9.2.1. North America market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.2.2. U.S.
- 9.2.2.1. Key country dynamics
- 9.2.2.2. Regulatory framework
- 9.2.2.3. Competitive scenario
- 9.2.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.2.2.5. Target disease prevalence
- 9.2.3. Canada
- 9.2.3.1. Key country dynamics
- 9.2.3.2. Regulatory framework
- 9.2.3.3. Competitive scenario
- 9.2.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.2.3.5. Target disease prevalence
- 9.3. Europe
- 9.3.1. Europe market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.2. UK
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Regulatory framework
- 9.3.2.3. Competitive scenario
- 9.3.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.2.5. Target disease prevalence
- 9.3.3. Germany
- 9.3.3.1. Key country dynamics
- 9.3.3.2. Regulatory framework
- 9.3.3.3. Competitive scenario
- 9.3.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.3.5. Target disease prevalence
- 9.3.4. France
- 9.3.4.1. Key country dynamics
- 9.3.4.2. Regulatory framework
- 9.3.4.3. Competitive scenario
- 9.3.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.4.5. Target disease prevalence
- 9.3.5. Italy
- 9.3.5.1. Key country dynamics
- 9.3.5.2. Regulatory framework
- 9.3.5.3. Competitive scenario
- 9.3.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.5.5. Target disease prevalence
- 9.3.6. Spain
- 9.3.6.1. Key country dynamics
- 9.3.6.2. Regulatory framework
- 9.3.6.3. Competitive scenario
- 9.3.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.6.5. Target disease prevalence
- 9.3.7. Norway
- 9.3.7.1. Key country dynamics
- 9.3.7.2. Regulatory framework
- 9.3.7.3. Competitive scenario
- 9.3.7.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.7.5. Target disease prevalence
- 9.3.8. Sweden
- 9.3.8.1. Key country dynamics
- 9.3.8.2. Regulatory framework
- 9.3.8.3. Competitive scenario
- 9.3.8.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.8.5. Target disease prevalence
- 9.3.9. Denmark
- 9.3.9.1. Key country dynamics
- 9.3.9.2. Regulatory framework
- 9.3.9.3. Competitive scenario
- 9.3.9.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.3.9.5. Target disease prevalence
- 9.4. Asia Pacific
- 9.4.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.4.2. Japan
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Regulatory framework
- 9.4.2.3. Competitive scenario
- 9.4.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.4.2.5. Target disease prevalence
- 9.4.3. China
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Regulatory framework
- 9.4.3.3. Competitive scenario
- 9.4.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.4.3.5. Target disease prevalence
- 9.4.4. India
- 9.4.4.1. Key country dynamics
- 9.4.4.2. Regulatory framework
- 9.4.4.3. Competitive scenario
- 9.4.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.4.4.5. Target disease prevalence
- 9.4.5. Australia
- 9.4.5.1. Key country dynamics
- 9.4.5.2. Regulatory framework
- 9.4.5.3. Competitive scenario
- 9.4.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.4.5.5. Target disease prevalence
- 9.4.6. South Korea
- 9.4.6.1. Key country dynamics
- 9.4.6.2. Regulatory framework
- 9.4.6.3. Competitive scenario
- 9.4.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.4.6.5. Target disease prevalence
- 9.4.7. Thailand
- 9.4.7.1. Key country dynamics
- 9.4.7.2. Regulatory framework
- 9.4.7.3. Competitive scenario
- 9.4.7.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.4.7.5. Target disease prevalence
- 9.5. Latin America
- 9.5.1. Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.5.2. Brazil
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework
- 9.5.2.3. Competitive scenario
- 9.5.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.5.2.5. Target disease prevalence
- 9.5.3. Mexico
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework
- 9.5.3.3. Competitive scenario
- 9.5.3.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.5.3.5. Target disease prevalence
- 9.5.4. Argentina
- 9.5.4.1. Key country dynamics
- 9.5.4.2. Regulatory framework
- 9.5.4.3. Competitive scenario
- 9.5.4.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.5.4.5. Target disease prevalence
- 9.6. MEA
- 9.6.1. MEA market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.2. South Africa
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework
- 9.6.2.3. Competitive scenario
- 9.6.2.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.2.5. Target disease prevalence
- 9.6.3. Saudi Arabia
- 9.6.3.1. Key country dynamics
- 9.6.3.2. Regulatory framework
- 9.6.3.3. Competitive scenario
- 9.6.3.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.3.5. Target disease prevalence
- 9.6.4. UAE
- 9.6.4.1. Key country dynamics
- 9.6.4.2. Regulatory framework
- 9.6.4.3. Competitive scenario
- 9.6.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.4.5. Target disease prevalence
- 9.6.5. Kuwait
- 9.6.5.1. Key country dynamics
- 9.6.5.2. Regulatory framework
- 9.6.5.3. Competitive scenario
- 9.6.5.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
- 9.6.5.5. Target disease prevalence
- Chapter 10. Competitive Landscape
- 10.1. Recent Developments & Impact Analysis, By Key Market Participants
- 10.2. Company/Competition Categorization
- 10.3. Vendor Landscape
- 10.3.1. List of key distributors and channel partners
- 10.3.2. Key customers
- 10.3.3. Key company position analysis, 2023
- 10.4. Company Profiles
- 10.4.1. QIAGEN
- 10.4.1.1. Company overview
- 10.4.1.2. Financial performance
- 10.4.1.3. Product benchmarking
- 10.4.1.4. Strategic initiatives
- 10.4.2. Bio-Techne Corp.
- 10.4.2.1. Company overview
- 10.4.2.2. Financial performance
- 10.4.2.3. Product benchmarking
- 10.4.2.4. Strategic initiatives
- 10.4.3. Precision for Medicine
- 10.4.3.1. Company overview
- 10.4.3.2. Financial performance
- 10.4.3.3. Product benchmarking
- 10.4.3.4. Strategic initiatives
- 10.4.4. AVIVA Biosciences
- 10.4.4.1. Company overview
- 10.4.4.2. Financial performance
- 10.4.4.3. Product benchmarking
- 10.4.4.4. Strategic initiatives
- 10.4.5. BIOCEPT, Inc.
- 10.4.5.1. Company overview
- 10.4.5.2. Financial performance
- 10.4.5.3. Product benchmarking
- 10.4.5.4. Strategic initiatives
- 10.4.6. BioCEP Ltd.
- 10.4.6.1. Company overview
- 10.4.6.2. Financial performance
- 10.4.6.3. Product benchmarking
- 10.4.6.4. Strategic initiatives
- 10.4.7. Fluxion Biosciences, Inc.
- 10.4.7.1. Company overview
- 10.4.7.2. Financial performance
- 10.4.7.3. Product benchmarking
- 10.4.7.4. Strategic initiatives
- 10.4.8. Greiner Bio-One International GmbH
- 10.4.8.1. Company overview
- 10.4.8.2. Financial performance
- 10.4.8.3. Product benchmarking
- 10.4.8.4. Strategic initiatives
- 10.4.9. Ikonisys, Inc.
- 10.4.9.1. Company overview
- 10.4.9.2. Financial performance
- 10.4.9.3. Product benchmarking
- 10.4.9.4. Strategic initiatives
- 10.4.10. Miltenyi Biotec
- 10.4.10.1. Company overview
- 10.4.10.2. Financial performance
- 10.4.10.3. Product benchmarking
- 10.4.10.4. Strategic initiatives
- 10.4.11. IVDiagnostics
- 10.4.11.1. Company overview
- 10.4.11.2. Financial performance
- 10.4.11.3. Product benchmarking
- 10.4.11.4. Strategic initiatives
- 10.4.12. BioFluidica
- 10.4.12.1. Company overview
- 10.4.12.2. Financial performance
- 10.4.12.3. Product benchmarking
- 10.4.12.4. Strategic initiatives
- 10.4.13. Canopus Bioscience Ltd.
- 10.4.13.1. Company overview
- 10.4.13.2. Financial performance
- 10.4.13.3. Product benchmarking
- 10.4.13.4. Strategic initiatives
- 10.4.14. Biolidics Limited
- 10.4.14.1. Company overview
- 10.4.14.2. Financial performance
- 10.4.14.3. Product benchmarking
- 10.4.14.4. Strategic initiatives
- 10.4.15. Creativ MicroTech , Inc.
- 10.4.15.1. Company overview
- 10.4.15.2. Financial performance
- 10.4.15.3. Product benchmarking
- 10.4.15.4. Strategic initiatives
- 10.4.16. LungLife AI
- 10.4.16.1. Company overview
- 10.4.16.2. Financial performance
- 10.4.16.3. Product benchmarking
- 10.4.16.4. Strategic initiatives
- 10.4.17. Epic Sciences
- 10.4.17.1. Company overview
- 10.4.17.2. Financial performance
- 10.4.17.3. Product benchmarking
- 10.4.17.4. Strategic initiatives
- 10.4.18. Rarecells Diagnostics
- 10.4.18.1. Company overview
- 10.4.18.2. Financial performance
- 10.4.18.3. Product benchmarking
- 10.4.18.4. Strategic initiatives
- 10.4.19. ScreenCell
- 10.4.19.1. Company overview
- 10.4.19.2. Financial performance
- 10.4.19.3. Product benchmarking
- 10.4.19.4. Strategic initiatives
- 10.4.20. Menarini Silicon Biosystems
- 10.4.20.1. Company overview
- 10.4.20.2. Financial performance
- 10.4.20.3. Product benchmarking
- 10.4.20.4. Strategic initiatives
- 10.4.21. LineaRx, Inc. (Vitatex, Inc.)
- 10.4.21.1. Company overview
- 10.4.21.2. Financial performance
- 10.4.21.3. Product benchmarking
- 10.4.21.4. Strategic initiatives
- 10.4.22. Sysmex Corporation
- 10.4.22.1. Company overview
- 10.4.22.2. Financial performance
- 10.4.22.3. Product benchmarking
- 10.4.22.4. Strategic initiatives
- 10.4.23. STEMCELL Technologies, Inc.
- 10.4.23.1. Company overview
- 10.4.23.2. Financial performance
- 10.4.23.3. Product benchmarking
- 10.4.23.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook